share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/10/18 13:59

Moomoo AI 已提取核心信息

Ensysce Biosciences has announced a significant amendment to its bylaws, effective November 1, 2024, that will lower the quorum requirement for stockholder meetings. The amendment reduces the number of shares needed to constitute a quorum from a majority to one-third of the total votes entitled to be cast.This strategic change in corporate governance structure, approved on October 17, 2024, aims to facilitate more efficient stockholder meetings by making it easier to achieve the necessary quorum for conducting business. The amendment was formally disclosed through an SEC Form 8-K filing on October 18, 2024.
Ensysce Biosciences has announced a significant amendment to its bylaws, effective November 1, 2024, that will lower the quorum requirement for stockholder meetings. The amendment reduces the number of shares needed to constitute a quorum from a majority to one-third of the total votes entitled to be cast.This strategic change in corporate governance structure, approved on October 17, 2024, aims to facilitate more efficient stockholder meetings by making it easier to achieve the necessary quorum for conducting business. The amendment was formally disclosed through an SEC Form 8-K filing on October 18, 2024.
Ensysce 生物科学公司已经宣布对其章程进行重大修订,该修订将于2024年11月1日生效,降低股东会议的法定人数要求。修订将法定人数所需的股份数从过半数降低到三分之一的总投票权。这一企业治理结构的战略性变化于2024年10月17日获得批准,旨在通过简化实现必要法定人数以便开展业务,从而促进更高效的股东会议。此修订于2024年10月18日通过证券交易委员会的8-k表格正式披露。
Ensysce 生物科学公司已经宣布对其章程进行重大修订,该修订将于2024年11月1日生效,降低股东会议的法定人数要求。修订将法定人数所需的股份数从过半数降低到三分之一的总投票权。这一企业治理结构的战略性变化于2024年10月17日获得批准,旨在通过简化实现必要法定人数以便开展业务,从而促进更高效的股东会议。此修订于2024年10月18日通过证券交易委员会的8-k表格正式披露。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息